
KOD Stock Forecast & Price Target
KOD Analyst Ratings
Bulls say
Kodiak Sciences is expected to continue its positive momentum with the development of its innovative ABC platform, which has shown promising results in its investigational medicines. The recent positive topline results from the Phase 3 GLOW2 trial for tarcocimab tedromer in diabetic retinopathy, combined with the prior successful trials for tarcocimab in other retinal diseases, support our thesis that the ABC platform can provide extended dosing regimens and improved efficacy without significant safety concerns. With an increased probability of success for tarcocimab tedromer and KSI-501, we see a potential for strong commercial revenues in the future. However, like any developmental-stage biopharmaceutical company, there are risks to consider, such as the failure to secure capital resources and potential setbacks in program development and commercialization. Looking ahead, we are anticipating further positive results from ongoing trials and are particularly interested in seeing readthrough from the early clinical data for KSI-101 to the pivotal trial profile for KSI-501.
Bears say
Kodiak Sciences is facing potential setbacks with their ABC platform and investigational medicines, specifically with failures in clinical trials for DME and wet AMD. With upcoming Phase 3 data for tarcocimab in DR, there is potential for validation of the reformulated design, but the overall efficacy profile for the ABC platform is still uncertain and may hinder their success in the retinal therapy market. Overall, there are significant questions surrounding Kodiak's capabilities and their ability to differentiate themselves, making their stock an unappealing investment at this time.
This aggregate rating is based on analysts' research of Kodiak Sciences Inc and is not a guaranteed prediction by Public.com or investment advice.
KOD Analyst Forecast & Price Prediction
Start investing in KOD
Order type
Buy in
Order amount
Est. shares
0 shares